Thalidomide. A new beginning.
Valorie
A M
AM
Philadelphia College of Pharmacy and Science, Philadelphia, Pennsylvania, USA.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D011307:Drug Prescriptions; D005544:Forecasting; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D013792:Thalidomide